Literature DB >> 22806818

Statistical approach for assessing the influence of calcium silicate and HPMC on the formulation of novel alfuzosin hydrochloride mucoadhesive-floating beads as gastroretentive drug delivery systems.

Rania Hassan Fahmy1.   

Abstract

Multiparticulate floating drug delivery systems have proven potential as controlled-release gastroretentive drug delivery systems that avoid the "all or none" gastric emptying nature of single-unit floating dosage forms. An objective of the presence investigation was to develop calcium silicate (CaSi)/calcium alginate (Ca-Alg)/hydroxypropyl methylcellulose (HPMC) mucoadhesive-floating beads that provide time- and site-specific drug release of alfuzosin hydrochloride (Alf). Beads were prepared by simultaneous internal and external gelation method utilizing 3(2) factorial design as an experimental design; with two main factors evaluated for their influence on the prepared beads; the concentration of CaSi as floating aid (X (1)) and the percentage of HPMC as viscosity enhancer and mucoadhesive polymer (X (2)), each of them was tested in three levels. Developed formulations were evaluated for yield, entrapment efficiency, particle size, surface topography, and buoyancy. Differential scanning calorimetry, Fourier transform infrared spectroscopy, in vitro drug release, as well as in vitro mucoadhesion using rat stomach mucosal membrane were also conducted. Percentage yield and entrapment efficiency ranged from 57.03% to 78.51% and from 49.78% to 83.26%, respectively. Statistical analysis using ANOVA proved that increasing the concentration of either CaSi or HPMC significantly increased the beads yield. Both CaSi and HPMC concentrations were found to significantly affect Alf release from the beads. Additionally, higher CaSi concentration significantly increased the beads diameter while HPMC concentration showed significant positive effect on the beads mucoadhesive properties. CaSi/Ca-Alg/HPMC beads represent simple floating-mucoadhesive gastroretentive system that could be useful in chronopharmacotherapy of benign prostatic hyperplasia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22806818      PMCID: PMC3429678          DOI: 10.1208/s12249-012-9823-2

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  35 in total

Review 1.  Formulation strategies for absorption windows.

Authors:  Stanley S Davis
Journal:  Drug Discov Today       Date:  2005-02-15       Impact factor: 7.851

Review 2.  Floating drug delivery systems: a review.

Authors:  Shweta Arora; Javed Ali; Alka Ahuja; Roop K Khar; Sanjula Baboota
Journal:  AAPS PharmSciTech       Date:  2005-10-19       Impact factor: 3.246

3.  Calcium silicate based microspheres of repaglinide for gastroretentive floating drug delivery: preparation and in vitro characterization.

Authors:  Sunil K Jain; A M Awasthi; N K Jain; G P Agrawal
Journal:  J Control Release       Date:  2005-10-03       Impact factor: 9.776

4.  Calcium alginate microparticles for oral administration: II. Effect of formulation factors on drug release and drug entrapment efficiency.

Authors:  F Acartürk; S Takka
Journal:  J Microencapsul       Date:  1999 May-Jun       Impact factor: 3.142

5.  Calcium alginate microparticles for oral administration: I: Effect of sodium alginate type on drug release and drug entrapment efficiency.

Authors:  S Takka; F Acartürk
Journal:  J Microencapsul       Date:  1999 May-Jun       Impact factor: 3.142

6.  High prevalence of benign prostatic hypertrophy in the community.

Authors:  W M Garraway; G N Collins; R J Lee
Journal:  Lancet       Date:  1991-08-24       Impact factor: 79.321

Review 7.  Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia.

Authors:  David R P Guay
Journal:  Am J Geriatr Pharmacother       Date:  2004-03

8.  Effect of HPMC and Carbopol on the release and floating properties of Gastric Floating Drug Delivery System using factorial design.

Authors:  Shoufeng Li; Senshang Lin; Bruce P Daggy; Haresh L Mirchandani; Yie W Chien
Journal:  Int J Pharm       Date:  2003-03-06       Impact factor: 5.875

Review 9.  Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia.

Authors:  Kate McKeage; Greg L Plosker
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 10.  Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.

Authors:  M I Wilde; A Fitton; D McTavish
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

View more
  2 in total

1.  Denatured Whey Protein Powder as a New Matrix Excipient: Design and Evaluation of Mucoadhesive Tablets for Sustained Drug Release Applications.

Authors:  Hassana Hsein; Ghislain Garrait; Fahima Tamani; Eric Beyssac; Valérie Hoffart
Journal:  Pharm Res       Date:  2016-12-21       Impact factor: 4.200

2.  Gastroretentive Sustained-Release Tablets Combined with a Solid Self-Micro-Emulsifying Drug Delivery System Adsorbed onto Fujicalin®.

Authors:  Yoshihiro Omachi
Journal:  AAPS PharmSciTech       Date:  2022-06-08       Impact factor: 3.246

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.